Jagsonpal Pharmaceuticals Employee Stock Options

Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways

Q2FY27 consolidated revenue ₹964 Mn (+29%, Aequitas consolidated); standalone revenue ₹814 Mn (+9.3%), EBITDA margin 22.7%, PAT ₹126 Mn flat. H1 standalone PAT +10.3%.

Jagsonpal Pharmaceuticals Results Update

Jagsonpal reported Q2 FY27 consolidated revenue up 29% to ₹964 Mn, with standalone revenue up 9.3%. Standalone H1 PAT grew 10.3% and cash stood at ₹1,347 Mn.

Jagsonpal Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.6 Cr, Up 0.0% YoY

Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+9.3% YoY) and net profit of ₹12.6 Cr (+0.0% YoY) for Q2 FY27.

Key figure

Net profit ₹12.6 Cr · +0.0% YoY

Jagsonpal Pharmaceuticals Board Meeting Date

Jagsonpal Pharmaceuticals Ltd will hold a Board Meeting on October 28, 2026, to consider and approve the company's unaudited financial results for the quarter ended September 30, 2026.

Jagsonpal Pharmaceuticals Other Announcement

Jagsonpal Pharmaceuticals Ltd filed its quarterly shareholding pattern statement in compliance with SEBI Regulation 31(1)(b).

Jagsonpal Pharmaceuticals Acquisition

Jagsonpal Pharmaceuticals has completed the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited, following the fulfilment of all conditions precedent in the agreement.

From

Group Pharmaceuticals Limited

Aye Finance Employee Stock Options

Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.

Aarti Pharmalabs Employee Stock Options

Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.

OnEMI Technology Solutions Employee Stock Options

OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.

Bliss GVS Pharma Employee Stock Options

Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.

Bandhan Bank Employee Stock Options

Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.

Maxvolt Energy Industries Employee Stock Options

Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.

Execution

Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date